Atlas Protocol · Clinical Prevention

Atlas Tumor Diseases Module

54-gene tumor-pathway module: somatic-pathway and tumor-predisposition genes.

A 54-gene tumor-disease module focused on somatic-pathway and tumor-predisposition genes that complement hereditary-cancer testing.

GenDG §10

This is a predictive genetic test.

The order page will ask you to either book counseling or waive counseling in writing per German GenDG §10. Your choice is fully documented and accessible at any time.

HOW IT WORKS

How it works.

  1. 01

    Easy at-home test

    Order in three clicks, no login. Kit ships from Berlin within 5 working days.

  2. 02

    Get your report and personalized action plan

    Follow the guided sample collection. Your AI-interpreted clinical report arrives by secure email.

  3. 03

    Consult with professionals and retest

    Discuss findings with your physician or our medical geneticist; retest as your interventions evolve.

WHICH PART OF YOUR BODY

Which part of your body.

  • Breasts
  • Ovaries
  • Colon
  • Stomach
  • Pancreas
  • Prostate
  • Skin
  • Thyroid
  • Endocrine glands
WHAT THIS PANEL ANSWERS

What this panel answers.

Do you carry inherited variants that raise your risk for breast, ovarian, colon, stomach, pancreatic, prostate, skin, thyroid, or endocrine tumors?

WHAT CHANGES IF A FINDING IS IDENTIFIED

What changes if something is found.

  1. BRCA1 and BRCA2 carriers in Germany may be eligible for the GC-HBOC intensified surveillance program at 17 university centers including Charité Berlin, with annual breast MRI typically starting at age 25 to 30 and covered by GKV.
  2. Lynch-syndrome carriers receive enhanced colorectal screening earlier than the population baseline, typically with annual colonoscopy starting around age 25.
  3. A pathogenic finding informs cascade testing for first-degree relatives, coordinated by a human-genetics specialist.
  4. Surgical prevention options exist for some carriers; these are discussed with a human-genetics specialist and a relevant surgical or oncology team, never decided based on a test alone.
  5. A negative result does not eliminate cancer risk and does not replace routine screening.
Pathway references
  • GC-HBOC
  • GKV
  • GenDG §7
GENES ANALYZED

What is analyzed.

Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are reviewed by a board-certified medical geneticist before release.

Atlas medical/product review pending.Atlas Tumor Diseases Module short copy implies somatic-pathway and tumor-predisposition coverage. Confirm with Atlas medical/product whether this module references the same 54-gene PRV01 set as Hereditary Cancer Comprehensive, or a distinct somatic-pathway panel. Until confirmed, the page surfaces PRV01 as a reference list.

PRV01

Tumor Diseases (Complete Gene Set)

54 genes

A 54-gene panel covering the high- and moderate-penetrance genes most commonly implicated in hereditary cancer syndromes -- breast/ovarian (BRCA1, BRCA2, PALB2), Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), Li-Fraumeni (TP53), familial adenomatous polyposis (APC), MEN syndromes, and several rarer tumor-predisposition syndromes.

Clinical areas covered
  • Digestive-tract cancers (colon, stomach, pancreatic)
  • Breast and ovarian cancer
  • Skin cancer (melanoma, basal-cell predisposition syndromes)
  • Thyroid and other endocrine tumors
  • Prostate cancer
Analyzed genes -- 54 genes
  • APC
  • ATM
  • AXIN2
  • BAP1
  • BARD1
  • BMPR1A
  • BRCA1
  • BRCA2
  • BRIP1
  • CDC73
  • CDH1
  • CDKN2A
  • CHEK2
  • DICER1
  • EPCAM
  • FH
  • FLCN
  • KIT
  • MAX
  • MEN1
  • MET
  • MLH1
  • MSH2
  • MSH6
  • MUTYH
  • NBN
  • NF1
  • NF2
  • PALB2
  • PDGFRA
  • PMS2
  • POLD1
  • POLE
  • PTCH1
  • PTEN
  • RAD51C
  • RAD51D
  • RB1
  • RET
  • SDHA
  • SDHAF2
  • SDHB
  • SDHC
  • SDHD
  • SMAD4
  • SMARCA4
  • SMARCB1
  • STK11
  • TMEM127
  • TP53
  • TSC1
  • TSC2
  • VHL
  • WT1

Gene list per CeGaT PRV01 (2026-05).

WHY THIS MATTERS

Why early knowledge matters.

  • PRV01

    Tumor Diseases (Complete Gene Set)

    Cancers detected at a local stage have five-year survival rates of 87% to 100% across most indications; survival drops sharply once a tumor has spread. Identifying a hereditary predisposition before symptoms appear lets a physician schedule risk-appropriate screening (often earlier and more frequent than the population baseline) and discuss preventive options with you.

RESULT INTERPRETATION

How findings are reported.

Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.

  1. 01

    Pathogenic variant

    Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.

  2. 02

    Likely pathogenic variant

    Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.

  3. 03

    Variant of uncertain significance (VUS)

    Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.

  4. 04

    No relevant variant in this panel

    No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.

  5. 05

    Family implications

    When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.

Module-specific implications
  • PRV01

    Tumor Diseases (Complete Gene Set)

    • A pathogenic finding informs a personalized screening schedule -- typically discussed with an oncologist or human geneticist.
    • Lynch-syndrome genes (MLH1, MSH2, MSH6, PMS2) also raise colorectal, endometrial, gastric, and urinary-tract cancer risk -- not only breast/ovarian.
    • First-degree relatives may benefit from cascade testing for an identified variant -- a decision made together with a counselor.
Counseling and cascade testing

Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.

CLINICAL LIMITATIONS

What this test does not do.

  • Not a diagnosis of active disease

    A variant indicates predisposition. It does not confirm a condition is currently present.

  • Does not replace screening or routine care

    Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.

  • Not all risk is genetic

    Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.

  • A negative result does not eliminate risk

    Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.

  • Clinical decisions remain with your physician

    Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.

GenDG §7

Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.

Ready to start? €690 · 3–4 weeks after sample arrival

Order →

Not sure if this is the right protocol? Let Atlas walk you through a few questions. Start Triage →

Or browse all 24 protocols: Open the Console →

Not ready? Book a counseling session first →

Already have your genome with Atlas?

See Atlas Baseline